Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation

Özet

To the best of our knowledge, non-vitamin K antagonist oral anticoagulants (NOACs), or direct oral anticoagulants, have not been tested in randomized trials conducted in patients with atrial fibrillation (AF), affected by malignant disease. However, their use in patients with cancer is increasing,while real-life evidence for their effectiveness and safety in this vulnerable subset of patients is growing. The challenges of the use of NOACs incancer patients with AF and current expert opinion on this subject have been summarized in this review article. (Anatol J Cardiol 2020; 23: 10-8)